ZA96897B - Methods of inhibiting effects of IL-6. - Google Patents

Methods of inhibiting effects of IL-6.

Info

Publication number
ZA96897B
ZA96897B ZA9600897A ZA96897A ZA96897B ZA 96897 B ZA96897 B ZA 96897B ZA 9600897 A ZA9600897 A ZA 9600897A ZA 96897 A ZA96897 A ZA 96897A ZA 96897 B ZA96897 B ZA 96897B
Authority
ZA
South Africa
Prior art keywords
methods
inhibiting effects
inhibiting
effects
Prior art date
Application number
ZA9600897A
Other languages
English (en)
Inventor
Andrew Lawrence Glasebrook
Steven Harold Zuckerman
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA96897B publication Critical patent/ZA96897B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
ZA9600897A 1995-02-06 1996-02-05 Methods of inhibiting effects of IL-6. ZA96897B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38473095A 1995-02-06 1995-02-06

Publications (1)

Publication Number Publication Date
ZA96897B true ZA96897B (en) 1997-08-05

Family

ID=23518514

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9600897A ZA96897B (en) 1995-02-06 1996-02-05 Methods of inhibiting effects of IL-6.

Country Status (14)

Country Link
EP (1) EP0724879A2 (en:Method)
JP (1) JPH10513470A (en:Method)
KR (1) KR19980701933A (en:Method)
CN (1) CN1173819A (en:Method)
AU (1) AU708374B2 (en:Method)
CA (1) CA2212232A1 (en:Method)
CZ (1) CZ246597A3 (en:Method)
FI (1) FI973235A0 (en:Method)
HU (1) HUP9801829A3 (en:Method)
IL (1) IL117036A0 (en:Method)
NO (1) NO973609L (en:Method)
WO (1) WO1996024356A1 (en:Method)
YU (1) YU6996A (en:Method)
ZA (1) ZA96897B (en:Method)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998046588A2 (en) 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6025373A (en) * 1997-04-22 2000-02-15 Eli Lilly And Company Methods for reducing fibrinogen
WO1999051587A1 (en) * 1998-04-01 1999-10-14 Ono Pharmaceutical Co., Ltd. Fused thiophene derivatives and drugs containing the same as the active ingredient
US6960577B2 (en) 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
JP2002533456A (ja) * 1998-12-30 2002-10-08 シグナル ファーマシューティカルズ， インコーポレイテッド エストロゲン受容体のモジュレートを行うための化合物および方法
ES2156550B1 (es) * 1999-04-19 2002-02-01 Univ Navarra Publica Derivados de benzo(b) tiofenosulfonamida-1,1-dioxido y su uso como agentes antineoplasicos.
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US20040167112A1 (en) * 2003-01-06 2004-08-26 Wyeth Use of estrogen receptor alpha modulators for the treatment of multiple sclerosis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
TW303299B (en:Method) * 1993-07-22 1997-04-21 Lilly Co Eli
US5708009A (en) * 1993-12-21 1998-01-13 Eli Lilly And Company Methods of inhibiting myeloperoxidase activity
US5574047A (en) * 1993-12-21 1996-11-12 Eli Lilly And Company Methods of inhibiting imperfect tissue repair
US5521198A (en) * 1993-12-21 1996-05-28 Eli Lilly And Company Methods of inhibiting autoimmune diseases
US5567820A (en) * 1994-05-20 1996-10-22 Eli Lilly And Company Glucopyranoside benzothiophenes

Also Published As

Publication number Publication date
CZ246597A3 (cs) 1998-06-17
AU708374B2 (en) 1999-08-05
HUP9801829A2 (hu) 1999-05-28
FI973235A7 (fi) 1997-08-05
KR19980701933A (ko) 1998-06-25
AU4916396A (en) 1996-08-27
EP0724879A2 (en) 1996-08-07
WO1996024356A1 (en) 1996-08-15
MX9705940A (es) 1997-10-31
FI973235L (fi) 1997-08-05
NO973609L (no) 1997-09-11
CA2212232A1 (en) 1996-08-15
IL117036A0 (en) 1996-06-18
JPH10513470A (ja) 1998-12-22
FI973235A0 (fi) 1997-08-05
CN1173819A (zh) 1998-02-18
NO973609D0 (no) 1997-08-05
EP0724879A3 (en:Method) 1996-09-11
HUP9801829A3 (en) 1999-10-28
YU6996A (sh) 1999-03-04

Similar Documents

Publication Publication Date Title
PL321759A1 (en) Novel thrombosin inhibitors
EG23871A (en) Protein kinase c inhibitor
IL122923A0 (en) Cyclic gmp-specific phosphodiesterase inhibitors
PH31599A (en) Methods of inhibiting autoimmune diseases.
ZA969221B (en) Indolealkyl derivatives of benzodioxanmethylamine.
ZA965922B (en) Preparation of N-substituted 3-hydroxypyrazoles.
PH31326A (en) Methods of inhibiting breast disorders.
IL122338A0 (en) Methods of inhibiting phagocytosis
GB2306848B (en) Hydrophone
ZA964682B (en) Methods of inhibiting melanoma.
IL117036A0 (en) Methods of inhibiting effects of il-6
GB9505865D0 (en) Hydrate Inhibitors
ZA967282B (en) Zwitterionic forms of trovafloxacin.
GB9510563D0 (en) Well inhibition
ZA961564B (en) Methods of inhibiting ovarian cancer.
GB9514866D0 (en) Overflow prevention plug
SG64924A1 (en) Inhibiting photodecompostion of 3-substituted-2- oxindoles
GB9722556D0 (en) Methods
AU7399298A (en) Methods of inhibiting corrosion using N-haloazoles
GB2305201B (en) Water defence block
GB2323095B (en) Wax Deposit Inhibitors
GB9516940D0 (en) Methods
GB9510639D0 (en) Methods
GB9505905D0 (en) Methods
GB9516970D0 (en) Methods